Eustralis Pharmaceuticals

Eustralis Pharmaceuticals is an Australian private biopharmaceutical company that operates under the trading name PresSura Neuro. The company is focused on developing therapeutics for severe traumatic brain injury, concussion-related conditions including chronic traumatic encephalopathy and post-concussion syndrome, stroke, and other neurological disorders with high unmet need. Its lead disclosed program, EU-C-001, is an NK1 receptor antagonist licensed from F. Hoffmann-La Roche and has been studied in Phase 1 and Phase 2 clinical trials. The business appears to be centered on neurotrauma and neurocritical-care indications rather than a broad multi-asset platform. Key scientific leadership includes founder and director Dr Robert Vink, with management highlighting experience in late-stage drug development.